{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:01:09Z","timestamp":1790438469261,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102905"],"award-info":[{"award-number":["82102905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010814","name":"Department of Education of Anhui Province","doi-asserted-by":"publisher","award":["2022AH010077"],"award-info":[{"award-number":["2022AH010077"]}],"id":[{"id":"10.13039\/501100010814","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117313","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T21:23:17Z","timestamp":1787779397000},"page":"117313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer"],"prefix":"10.1016","volume":"188","author":[{"given":"Haiyang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.117313_bb0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.117313_bb0010","first-page":"2892","article-title":"EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)","volume":"5","author":"Midha","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117313_bb0015","first-page":"387","article-title":"Personalized care for patients with EGFR-mutant non-small-cell lung cancer: navigating early to advanced disease management","volume":"75","author":"Borgeaud","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.117313_bb0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.intimp.2026.117313_bb0025","first-page":"608","article-title":"Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors","volume":"4","author":"Luo","year":"2014","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117313_bb0030","doi-asserted-by":"crossref","first-page":"E822","DOI":"10.1002\/ijc.27396","article-title":"Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials","volume":"131","author":"Gao","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2026.117313_bb0035","first-page":"36","article-title":"Targeted therapy for non-small cell lung cancer: current standards and the promise of the future","volume":"4","author":"Chan","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.intimp.2026.117313_bb0040","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JOP.2015.008524","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update","volume":"12","author":"Masters","year":"2016","journal-title":"J. Oncol. Pract."},{"issue":"Suppl. 5","key":"10.1016\/j.intimp.2026.117313_bb0045","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdq189","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"D\u2019Addario","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1308460","article-title":"The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors","volume":"13","author":"Bronte","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0060","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2026.117313_bb0070","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jtho.2023.09.1453","article-title":"Real-world genomic profile of EGFR second-site mutations and other osimertinib resistance mechanisms and clinical landscape of NSCLC post-osimertinib","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117313_bb0080","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1183\/09059180.00008413","article-title":"First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology","volume":"23","author":"Sebastian","year":"2014","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.intimp.2026.117313_bb0085","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2026.117313_bb0090","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0095","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr.2016.12.02","article-title":"Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance","volume":"5","author":"Minari","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.intimp.2026.117313_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122345","article-title":"CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3\/STAT3 signaling pathway","volume":"336","author":"Liu","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2026.117313_bb0105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jtho.2023.10.017","article-title":"MUC1-C is a common driver of acquired osimertinib resistance in NSCLC","volume":"19","author":"Haratake","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0110","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1152\/physrev.1999.79.4.1193","article-title":"Prostanoid receptors: structures, properties, and functions","volume":"79","author":"Narumiya","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.intimp.2026.117313_bb0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.117313_bb0120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jtho.2022.12.003","article-title":"Single-cell analysis reveals transcriptomic features of drug-tolerant persisters and stromal adaptation in a patient-derived EGFR-mutated lung adenocarcinoma xenograft model","volume":"18","author":"Moghal","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0125","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/pr.120.019331","article-title":"International Union of Basic and Clinical Pharmacology. CIX. Differences and similarities between human and rodent prostaglandin E2 receptors (EP1\u20134) and prostacyclin receptor (IP): specific roles in pathophysiologic conditions","volume":"72","author":"Norel","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.intimp.2026.117313_bb0130","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1111\/bph.13331","article-title":"Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets?","volume":"172","author":"O\u2019Callaghan","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117313_bb0135","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00404-020-05559-6","article-title":"COX-2-PGE2-EPs in gynecological cancers","volume":"7301","author":"Ye","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.intimp.2026.117313_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2020.106409","article-title":"Prostaglandin E2 as a therapeutic target in bladder cancer: from basic science to clinical trials","volume":"148","author":"Woolbright","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.intimp.2026.117313_bb0145","doi-asserted-by":"crossref","first-page":"39672","DOI":"10.1074\/jbc.M110.117689","article-title":"The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and \u03b2-arrestin1-dependent signaling pathways","volume":"285","author":"Chun","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2026.117313_bb0150","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-020-03160-0","article-title":"Restoring metabolism of myeloid cells reverses cognitive decline in ageing","volume":"590","author":"Minhas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117313_bb0155","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nbt.3772","article-title":"Toil enables reproducible, open source, big biomedical data analyses","volume":"35","author":"Vivian","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.intimp.2026.117313_bb0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.lungcan.2009.09.014","article-title":"Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors","volume":"69","author":"Sun","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2026.117313_bb0165","article-title":"Expression patterns of Ezrin and AJAP1 and clinical significance in breast cancer","volume":"12","author":"Xu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0170","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nature11986","article-title":"Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1","volume":"496","author":"Tannahill","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.117313_bb0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molcel.2019.10.023","article-title":"Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor","volume":"77","author":"Wu","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.intimp.2026.117313_bb0180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cytogfr.2018.04.002","article-title":"Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer","volume":"41","author":"Ray","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.intimp.2026.117313_bb0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41419-020-03335-7","article-title":"Gefitinib initiates sterile inflammation by promoting IL-1\u03b2 and HMGB1 release via two distinct mechanisms","volume":"12","author":"Noguchi","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.117313_bb0190","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.ymthe.2019.05.017","article-title":"Hypoxia induces drug resistance in colorectal cancer through the HIF-1\u03b1\/miR-338-5p\/IL-6 feedback loop","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117313_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ultsonch.2024.107115","article-title":"Alleviating tumor hypoxia and immunosuppression via sononeoperfusion: a new ally for potentiating anti-PD-L1 blockade of solid tumor","volume":"112","author":"Yang","year":"2025","journal-title":"Ultrason. Sonochem."},{"key":"10.1016\/j.intimp.2026.117313_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107438","article-title":"Drug resistance to targeted therapeutic strategies in non-small cell lung cancer","volume":"206","author":"Liu","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.117313_bb0205","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision diagnosis and treatment for advanced non-small-cell lung cancer","volume":"377","author":"Reck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.117313_bb0210","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.117313_bb0215","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.19.03123","article-title":"Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review","volume":"38","author":"Piper-Vallillo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117313_bb0220","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neo.2017.11.001","article-title":"Navigating the \u201cno man\u2019s land\u201d of TKI-failed EGFR-mutated non-small cell lung cancer (NSCLC): a review","volume":"20","author":"Oronsky","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2026.117313_bb0225","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mc.22524","article-title":"Prostaglandin E2 stimulates urokinase-type plasminogen activator receptor via EP2 receptor-dependent signaling pathways in human AGS gastric cancer cells","volume":"56","author":"Lian","year":"2017","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.intimp.2026.117313_bb0230","first-page":"4680","article-title":"Inhibition of EP2 receptor suppresses tumor growth and chemoresistance of gastric cancer","volume":"12","author":"Shin","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117313_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1209572","article-title":"PGE2-EP2\/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer","volume":"14","author":"Akbari","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117313_bb0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4062\/biomolther.2020.048","article-title":"Thymoquinone suppresses migration of human renal carcinoma Caki-1 cells through inhibition of the PGE2-mediated activation of the EP2 receptor pathway","volume":"29","author":"Park","year":"2021","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.intimp.2026.117313_bb0245","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1096\/fj.06-7581com","article-title":"EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1\/2 pathways","volume":"21","author":"Donnini","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.intimp.2026.117313_bb0250","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/labinvest.2012.90","article-title":"Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model","volume":"92","author":"Xin","year":"2012","journal-title":"Lab. Investig."},{"key":"10.1016\/j.intimp.2026.117313_bb0255","article-title":"Gys1 regulates maternal glycogen reserve essential for embryonic development in zebrafish","volume":"10","author":"Chen","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2026.117313_bb0260","doi-asserted-by":"crossref","first-page":"9186","DOI":"10.7150\/thno.46825","article-title":"GYS1 induces glycogen accumulation and promotes tumor progression via the NF-\u03baB pathway in clear cell renal carcinoma","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.117313_bb0265","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fncel.2015.00431","article-title":"Role of brain glycogen in the response to hypoxia and in susceptibility to epilepsy","volume":"9","author":"L\u00f3pez-Ramos","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.intimp.2026.117313_bb0270","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ymgme.2009.07.012","article-title":"Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts","volume":"98","author":"Cameron","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.intimp.2026.117313_bb0275","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.1128\/MCB.24.16.7179-7187.2004","article-title":"Abnormal cardiac development in the absence of heart glycogen","volume":"24","author":"Pederson","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2026.117313_bb0280","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.cmet.2012.10.017","article-title":"Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells","volume":"16","author":"Favaro","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.intimp.2026.117313_bb0285","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2015.46","article-title":"Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells","volume":"29","author":"Bhanot","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.117313_bb0290","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13046-021-02082-7","article-title":"The HIF1\u03b1-PDGFD-PDGFR\u03b1 axis controls glioblastoma growth at normoxia\/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin","volume":"40","author":"Peng","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.117313_bb0295","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1111\/ajt.17124","article-title":"E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation","volume":"22","author":"Ling","year":"2022","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2026.117313_bb0300","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41388-022-02506-4","article-title":"GPER-mediated stabilization of HIF-1\u03b1 contributes to upregulated aerobic glycolysis in tamoxifen-resistant cells","volume":"42","author":"Zhang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.117313_bb0305","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1007\/s00018-015-1891-5","article-title":"Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells","volume":"72","author":"Fern\u00e1ndez-Mart\u00ednez","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.intimp.2026.117313_bb0310","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.lungcan.2018.08.025","article-title":"Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer","volume":"125","author":"Jia","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.intimp.2026.117313_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106805","article-title":"Evaluation of drug resistance for EGFR-TKIs in lung cancer via multicellular lung-on-a-chip","volume":"199","author":"Tan","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.intimp.2026.117313_bb0320","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/j.1476-5381.2011.01495.x","article-title":"In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP2 receptor antagonist","volume":"164","author":"Forselles","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2026.117313_bb0325","first-page":"1096","article-title":"Selective EP2 and COX-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition, and COX-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer","volume":"12","author":"Watanabe","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.intimp.2026.117313_bb0330","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/0008-5472.CAN-25-0433","article-title":"Transfer of damaged mitochondria from cancer cells to cancer-associated fibroblasts promotes tyrosine kinase inhibitor tolerance in EGFR-mutant lung cancer","volume":"86","author":"Liu","year":"2026","journal-title":"Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:42:26Z","timestamp":1790437346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":66,"alternative-id":["S1567576926011604"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117313","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117313"}}